Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Life sciences tools and services firm Agilent Technologies outperformed as demand began to recover following an extended downturn in the industry after the COVID-19 pandemic and cuts to National Institutes of Health funding. Biotech funding and...
— The Ceredex Mid-Cap Value Equity Strategy
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Agilent Technologies, Inc.
No other institutional pitches found for this ticker yet.